Sung-eun C. Lee

St. Vincent Hospital
Suwon, Republic of Korea

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 305 publications

Cross-study analyses of the ropeginterferon alfa-2b effect on phlebotomy in low- and high-risk patients with polycythemia vera.

Cross-study analyses of the ropeginterferon alfa-2b effect on phlebotomy in low- and high-risk patients with polycythemia vera.

Journal: Leukemia & lymphoma

Published: July 17, 2026

Artificial Intelligence-Derived Electrocardiogram Analysis for Identification of Carbon Monoxide-Induced Cardiomyopathy: A Retrospective Study.

Artificial Intelligence-Derived Electrocardiogram Analysis for Identification of Carbon Monoxide-Induced Cardiomyopathy: A Retrospective Study.

Journal: Medicina (Kaunas, Lithuania)

Published: April 22, 2026

Analysis of Blood Group Antigens as Risk Factors for Thrombosis in Polycythemia Vera Patients.

Analysis of Blood Group Antigens as Risk Factors for Thrombosis in Polycythemia Vera Patients.

Journal: Clinical laboratory

Published: April 14, 2026

Efficacy and Safety of Ropeginterferon Alfa-2b in Pregnant Women With Myeloproliferative Neoplasms: Case Series of Three Subtypes and Review.

Efficacy and Safety of Ropeginterferon Alfa-2b in Pregnant Women With Myeloproliferative Neoplasms: Case Series of Three Subtypes and Review.

Journal: Journal of Korean medical science

Published: April 10, 2026

Asciminib as first-line therapy in chronic myeloid leukemia: a systematic review.

Asciminib as first-line therapy in chronic myeloid leukemia: a systematic review.

Journal: Blood research

Published: March 23, 2026

Asciminib Provides Better Efficacy and Favorable Safety and Tolerability Against Investigator-Selected Tyrosine Kinase Inhibitors in East Asian Patients With Newly Diagnosed Chronic Myeloid Leukemia: Results From a Subgroup Analysis of the Pivotal ASC4FIRST Study.

Asciminib Provides Better Efficacy and Favorable Safety and Tolerability Against Investigator-Selected Tyrosine Kinase Inhibitors in East Asian Patients With Newly Diagnosed Chronic Myeloid Leukemia: Results From a Subgroup Analysis of the Pivotal ASC4FIRST Study.

Journal: Cancer medicine

Published: March 20, 2026

Human NKT10 cells are enriched in cord-derived invariant natural killer T cells and mediate immune-regulation in a xenogeneic graft-versus-host disease model.

Human NKT10 cells are enriched in cord-derived invariant natural killer T cells and mediate immune-regulation in a xenogeneic graft-versus-host disease model.

Journal: Frontiers in immunology

Published: March 19, 2026

Real-world clinical outcomes of tisagenlecleucel in relapsed or refractory diffuse large B-cell lymphoma: a single-center retrospective study.

Real-world clinical outcomes of tisagenlecleucel in relapsed or refractory diffuse large B-cell lymphoma: a single-center retrospective study.

Journal: Frontiers in oncology

Published: March 05, 2026

Real-world outcomes of ponatinib in heavily pretreated patients with chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.

Real-world outcomes of ponatinib in heavily pretreated patients with chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.

Journal: Annals of hematology

Published: December 22, 2025

Ropeginterferon dose-escalation strategies in polycythemia vera: a systematic review and meta-analysis.

Ropeginterferon dose-escalation strategies in polycythemia vera: a systematic review and meta-analysis.

Journal: BMC cancer

Published: December 11, 2025

Spatial distributions, sources, and ecological risks of metals in soils from the largest industrial city of Ulsan, South Korea.

Spatial distributions, sources, and ecological risks of metals in soils from the largest industrial city of Ulsan, South Korea.

Journal: Environmental geochemistry and health

Published: November 17, 2025

Frontline ponatinib plus hyper-CVAD over imatinib in adults with Ph-positive acute lymphoblastic leukemia: realworld efficacy and risks of early ponatinib dose reduction.

Frontline ponatinib plus hyper-CVAD over imatinib in adults with Ph-positive acute lymphoblastic leukemia: realworld efficacy and risks of early ponatinib dose reduction.

Journal: Haematologica

Published: October 24, 2025

Showing 1-12 of 305

Last Updated: 09/26/2026